TIMP1 and AL amyloidosis: By elucidating the specific mechanisms underlying the dysregulation of MMP and TIMP, researchers can pave the way for novel treatment approaches aimed at restoring the balance of these crucial factors and ultimately improving the outcomes for multiple myeloma patients.